Pyxis Oncology, Inc. (NASDAQ:PYXS) Sees Large Drop in Short Interest

Pyxis Oncology, Inc. (NASDAQ:PYXSGet Rating) was the recipient of a significant decrease in short interest in April. As of April 30th, there was short interest totalling 343,200 shares, a decrease of 18.6% from the April 15th total of 421,500 shares. Approximately 1.6% of the company’s stock are sold short. Based on an average daily volume of 105,100 shares, the days-to-cover ratio is presently 3.3 days.

Separately, Zacks Investment Research upgraded Pyxis Oncology from a “sell” rating to a “hold” rating in a research note on Tuesday, January 18th. Two investment analysts have rated the stock with a hold rating and four have assigned a buy rating to the company. According to data from MarketBeat.com, the company has a consensus rating of “Buy” and a consensus target price of $20.00.

In related news, Director Mark Chin sold 1,745,761 shares of the company’s stock in a transaction that occurred on Thursday, April 21st. The stock was sold at an average price of $3.05, for a total value of $5,324,571.05. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website.

Several institutional investors and hedge funds have recently bought and sold shares of the stock. State Street Corp boosted its stake in shares of Pyxis Oncology by 55.9% during the first quarter. State Street Corp now owns 144,795 shares of the company’s stock valued at $585,000 after acquiring an additional 51,920 shares during the last quarter. Tekla Capital Management LLC boosted its stake in shares of Pyxis Oncology by 424.7% during the first quarter. Tekla Capital Management LLC now owns 708,303 shares of the company’s stock valued at $2,630,000 after acquiring an additional 573,303 shares during the last quarter. Vanguard Group Inc. boosted its stake in shares of Pyxis Oncology by 1.2% during the first quarter. Vanguard Group Inc. now owns 526,309 shares of the company’s stock valued at $2,126,000 after acquiring an additional 6,011 shares during the last quarter. BlackRock Inc. boosted its stake in shares of Pyxis Oncology by 1.4% during the first quarter. BlackRock Inc. now owns 520,901 shares of the company’s stock valued at $2,104,000 after acquiring an additional 7,053 shares during the last quarter. Finally, Citigroup Inc. lifted its position in Pyxis Oncology by 7,171.6% during the first quarter. Citigroup Inc. now owns 233,129 shares of the company’s stock worth $942,000 after buying an additional 229,923 shares during the period. 61.30% of the stock is currently owned by institutional investors and hedge funds.

Shares of Pyxis Oncology stock traded up $0.11 during trading hours on Tuesday, hitting $2.13. 13,322 shares of the company were exchanged, compared to its average volume of 287,216. Pyxis Oncology has a 1 year low of $1.96 and a 1 year high of $19.00. The business has a 50-day moving average of $3.63 and a 200-day moving average of $7.53.

Pyxis Oncology (NASDAQ:PYXSGet Rating) last announced its quarterly earnings data on Friday, May 13th. The company reported ($0.97) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.61) by ($0.36). As a group, equities research analysts anticipate that Pyxis Oncology will post -2.83 EPS for the current year.

About Pyxis Oncology (Get Rating)

Pyxis Oncology, Inc, a preclinical stage biopharmaceutical company, engages in the development of therapies to treat cancers. Its immune-oncology product candidates include PYX-106, an investigational fully human immunoglobulin G1 isotype siglec-15 targeting antibody for the treatment of thyroid cancer, head and neck squamous cell carcinoma, non-small cell lung cancer (NSCLC), and other solid tumors; and PYX-102, an investigational immune-therapeutic for treatment of solid tumors.

Featured Stories

Receive News & Ratings for Pyxis Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pyxis Oncology and related companies with MarketBeat.com's FREE daily email newsletter.